Nifty 50
- Apollo Hospitals₹8,027.50361.50 (4.72%)
- BSE₹3,287.20-47.60 (-1.43%)
- ITC₹26611.00 (4.31%)
- Reliance Industries₹1,170.30-7.70 (-0.65%)
- Eicher Motors₹7,050282.50 (4.17%)
- JSW Steel₹1,168-7.20 (-0.61%)
- TCS₹2,15680.00 (3.85%)
- Cipla₹1,301-5.80 (-0.44%)
- HCL Technologies₹1,216.7039.80 (3.38%)
- Adani Ports₹1,76153.00 (3.10%)
- Infosys₹1,023.4026.40 (2.65%)
- Shriram Finance₹940.4523.20 (2.53%)
- Tata Motors PV₹279.906.90 (2.53%)
- UltraTech Cement₹10,675249.00 (2.39%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Alkem Laboratories Launches Epilepsy Drug NeuCeno in India
Authored By PTI | Last Modified: Sep 17, 2026 10:30 AM IST
Open Free Demat Account
Open Free Demat Account
New Delhi: Alkem Laboratories on Wednesday announced the launch of NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.
The company stated that cenobamate is being launched for the first time in India, where an estimated 94 lakh people live with epilepsy.
NeuCeno is a once-daily oral therapy available in strengths ranging from 12.5 mg to 200 mg tablets.
In clinical studies of adults with uncontrolled focal seizures on existing medications, adjunctive cenobamate showed up to a 78 per cent reduction in seizure frequency, with up to 30 per cent of patients achieving seizure freedom during the maintenance phase, the company said in an exchange filing.
“People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management,” said Sandeep Singh, Managing Director of Alkem Laboratories.
(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)
Disclaimer
At HDFC SKY*, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations.
HDFC SKY from HDFC Securities, one of most trusted trading platforms in India, has been recognized with the *Next-Gen Digi Content Awards 2025-26.
Join Us
Add as preferred source on Google
Open Free Demat Account
Open Free Demat Account
₹5,279
Invest Anytime, Anywhere
By signing up I certify terms, conditions & privacy policy